Garren, Hideki

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 2,021

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 1,905

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 513